Literature DB >> 7794764

Atypical chronic lymphocytic leukaemia with t(11;14)(q13;q32): karyotype evolution and prolymphocytic transformation.

A Cuneo1, M Balboni, N Piva, G M Rigolin, M G Roberti, C Mejak, S Moretti, R Bigoni, R Balsamo, P Cavazzini.   

Abstract

In order to define better the cytological and clinical features of atypical B-cell chronic lymphocytic leukaemia (B-CLL) with t(11:14)(q13;q32), sequential morphologic immunological and cytogenetic studies were performed in seven patients belonging to a series of 72 consecutive cases presenting with a diagnosis of CLL or atypical CLL according to the FAB criteria. Cytologic diagnosis in these seven patients with t(11;14) was typical CLL in two cases presenting with < 10% large lymphocytes (LL) and prolymphocytes (PL) and atypical CLL in five cases in which LL and PL comprised between 10% and 55%. The diagnosis was supported by histologic findings on bone marrow biopsy (five cases) or splenectomy specimens (two cases). A progressive increase of peripheral LL and PL was observed, resulting in a switch of FAB diagnosis over a 6-60-month period from typical CLL into atypical CLL in two cases and from atypical CLL into prolymphocytic leukaemia in five cases. Immunophenotyping showed a mature B-cell phenotype with CD19, CD22, CD24 positivity and CD10 negativity in all patients. A bright-staining pattern for surface immunoglobulins (SIg) was detected in 6/7 cases, CD5 positivity in 6/7 cases, and CD23 positivity in 1/7 cases. The FMC-7 monoclonal antibody was positive in > 40% cells in 5/6 cases. Chromosome changes in addition to t(11;14) were seen in five cases; in two cases unbalanced translocations involving the 3q21 chromosome region, resulting in partial trisomy for the long arm of chromosome 3, were detected early in the course of the disease. Karyotype evolution that was associated with disease progression occurred in 3/6 assessable patients. Comparison of these findings with similar data from 65 B-CLL patients without t(11:14) showed that atypical morphology, switch of FAB diagnosis during the course of the disease, and karyotype evolution were more frequently seen in cases with t(11;14) (5/7 v 15/65 cases, P = 0.015, 7/7 v 7/65 cases, P < 0.0001, and 3/6 v 5/45 assessable cases, P = 0.04, respectively). The frequency of positivity for CD23 and bright SIg staining differed significantly in the two groups. It is concluded that t(11;14) identifies a cytologically atypical subset of B-CLL, characterized by frequent cytologic and cytogenetic evolution and by a distinct immunological profile, sharing some biological features with mantle cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794764     DOI: 10.1111/j.1365-2141.1995.tb05167.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

Review 2.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.

Authors:  Marc DE Braekeleer; Corine Tous; Nadia Guéganic; Marie-Josée LE Bris; Audrey Basinko; Frédéric Morel; Nathalie Douet-Guilbert
Journal:  Mol Clin Oncol       Date:  2016-02-26

4.  Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis.

Authors:  Ramya Muddasani; Neel Talwar; Jaime Andres Suarez-Londono; Marc Braunstein
Journal:  Clin Case Rep       Date:  2020-03-05

5.  The lymphocyte immunophenotypical pattern in chronic lymphocytic leukemia associated with hepatitis viral infections.

Authors:  H Bumbea; A M Vladareanu; A Vintilescu; S Radesi; C Ciufu; M Onisai; C Baluta; M Begu; C Dobrea; V Arama; A Streinu-Cercel; S Arama
Journal:  J Med Life       Date:  2011-08-25

6.  Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.

Authors:  J Vargova; K Vargova; N Dusilkova; V Kulvait; V Pospisil; J Zavadil; M Trneny; P Klener; T Stopka
Journal:  Blood Cancer J       Date:  2016-09-23       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.